Allergan plc: Allergan to Review Presentation at EASL in Paris of Year 2 Analysis of the Phase 2b CENTAUR Study Cenicriviroc (CVC) Treatment for Adults with Non-Alcoholic Steatohepatitis

Tickers: AGN
Allergan plc will host a conference call and webcast on Thursday, April 12, 2018 at 12:00p.m. EST to review the year 2 analysis of the Phase 2b CENTAUR Study of Cenicriviroc (CVC) for adults with Non-Alcoholic Steatohepatitis.

This data will be presented at the European Association for the Study of the Liver (EASL) Meeting earlier on Thursday, April 12, 2018 in Paris, France. Top-line data from the study was also presented in September 2017.

Top Company Interviews

Microsoft Corporation
Intel Corporation
Pfizer, Inc.
General Electric Company
Wal-Mart Stores, Inc.
Dial-in Information

U.S./Canada: (877) 251-7980
International: (706) 643-1573
Conference ID: 2689057

Replay Information

A replay of the conference call will be available approximately two hours after it ends and will remain available through 11:30p.m. ET on May 12, 2018. The replay may be accessed by dialing (855) 859-2056 or (404) 537-3406, and entering the Conference ID 2689057.

To access the webcast, please visit Allergan's Investor Relations website at www.allergan.com/investors/events-presentations

Disclaimer

Allergan plc published this content on 11 April 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 11 April 2018 21:23:08 UTC